Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase Ib/II Clinical Trial to Evaluate the Efficacy and Safety of Surufatinib in Combination With KN046 and AG Regimen Chemotherapy for the First-Line Treatment of Unresectable Advanced Pancreatic Cancer

NCT05832892 is registered in ClinicalTrials.gov with Shanghai Zhongshan Hospital as lead sponsor.

NCT NCT05832892
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05832892 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase Ib/II Clinical Trial to Evaluate the Efficacy and Safety of Surufatinib in Combination With KN046 and AG Regimen Chemotherapy for the First-Line Treatment of Unresectable Advanced Pancreatic Cancer
Lead sponsor
Shanghai Zhongshan Hospital
Phase
Phase 1/2
Overall status
Unknown status
Start date
November 1, 2023
Completion date
June 1, 2025
Enrollment
41 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

unresectable locally advanced or metastatic pancreatic cancer